Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.48 -0.34 (-1.56%)
Streaming Delayed Price Updated: 3:01 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
33 34 Next >
News headline image
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying ↗
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
RADNOR, PA - May 9, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of... 
Via TheNewswire.com
Topics Fraud
News headline image
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation Alert: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
RADNOR, PA - May 8, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of... 
Via TheNewswire.com
Topics Fraud
News headline image
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta... 
Via StockStory
Topics Artificial Intelligence
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
RADNOR, PA - May 7, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of... 
Via TheNewswire.com
Topics Fraud
News headline image
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 20.5% in the afternoon session after the company reported weak first quarter 2025 results which featured drastically lowered full-year... 
Via StockStory
News headline image
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up ↗
Sarepta posted a deeper-than-expected Q1 loss and cut its 2025 forecast due to Elevidys rollout delays, despite beating revenue estimates. 
Via Benzinga
News headline image
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low ↗
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment. 
Via Investor's Business Daily
Topics Death
News headline image
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
News headline image
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Sarepta Shares Slide To 2017 Lows On Revenue Cut, But Retail Bulls Remain Defiant ↗
Despite strong Q1 sales led by Elevidys, Sarepta raised spending forecasts and lowered full-year guidance, triggering a sharp market reaction. 
Via Stocktwits
News headline image
Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per... 
Via StockStory
News headline image
Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why ↗
Sarepta Therapeutics shares are sinking after the company releases its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.